Date of publication: April 12, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine Gamaleya. This assessment follows the continue reading : Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the Prevention of COVID-19
SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the prevention of COVID-19
Date of publication: April 09, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine CoronaVac. This assessment follows the continue reading : SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the prevention of COVID-19
Effectiveness and Safety of Pazopanib in the Management of Metastatic Soft Tissue Sarcoma Post-Chemotherapy
Evidence Summary: effectiveness and safety of pazopanib in the management of metastatic soft tissue sarcoma post-chemotherapy
COVID-19 Vaccine (ChAdOx1-S [Recombinant]) (COVID-19 Vaccine AstraZeneca) for the Prevention of COVID-19
Date of publication: February 02, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report is produced to present all currently available evidence considered in the assessment of Pfizer-BioNTech COVID-19 Vaccine. This continue reading : COVID-19 Vaccine (ChAdOx1-S [Recombinant]) (COVID-19 Vaccine AstraZeneca) for the Prevention of COVID-19
BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19
Date of publication: February 02, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report is produced to present all currently available evidence considered in the assessment of Pfizer-BioNTech COVID-19 Vaccine. This continue reading : BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) for the prevention of COVID-19